Answers are grounded in this paper and cite their sources.
Circulating tumor cells (CTCs) play a key role in cancer metastasis. However, the complex tumor microenvironment means that targeting these cells therapeutically remains a major clinical challenge. The natural compound GKB202, derived from the mycelium of Antrodia cinnamomea , has been shown to possess anti-cancer properties. Yet, its role in regulating signaling mechanisms preceding cancer metastasis remains unclear. In this study, RNA-seq analysis demonstrated that GKB202 treatment reduced endothelin-1 (ET-1) expression and downregulated signaling cascades in CTCs derived from pancreatic cancer patients. Furthermore, conditioned medium assays indicated that GKB202 prevented cancer cells from stimulating endothelial cells to produce ET-1 and activate ERK/p-ERK downstream signaling, suggesting its potential to inhibit CTCs and prevent the extravasation process. Using protein interaction prediction tools and pathway analysis (STRING and KEGG), we identified interactions between ET-1, MAPK, and AKT, which are associated with tumor angiogenesis pathways. Molecular docking analysis further revealed that GKB202 can act as an ET B receptor antagonist, with a binding energy comparable to that of Bosentan, a known ET B receptor blocker. In addition, combination index (CI) analysis demonstrated that GKB202 exhibited significant synergistic effects with 5-fluorouracil (5-FU), a first-line chemotherapeutic agent. Based on these findings, this study highlights the potential of GKB202 to inhibit cancer cell-induced ET-1 production in endothelial cells, providing novel insights into the tumor microenvironment. Furthermore, as a naturally derived small-molecule compound, GKB202 may serve as a promising candidate for future therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: